Inhibiting miR-647 increases IL-6R expression, activates the JAK1/STAT3 signaling pathway, upregulates PD-L1 expression, and promotes immune evasion and angiogenesis in ovarian cancer cells. Here, CD274 is linked to ovarian carcinoma.